Apellis Pharmaceuticals (APLS) Reports Q1 Earnings: What Key Metrics Have to Say

Core Insights - Apellis Pharmaceuticals, Inc. reported a revenue of $166.8 million for Q1 2025, reflecting a year-over-year decline of 3.2% and a significant EPS of -$0.74 compared to -$0.54 a year ago, indicating a worsening financial performance [1] - The revenue fell short of the Zacks Consensus Estimate of $192.44 million by 13.33%, and the EPS also missed the consensus estimate of -$0.36 by 105.56% [1] Revenue Breakdown - Product revenue was reported at $149.90 million, which is 8.1% lower than the year-ago quarter and below the average estimate of $181.79 million from 10 analysts [4] - Licensing and other revenue reached $16.90 million, exceeding the average estimate of $13.31 million and showing a year-over-year increase of 82.7% [4] - Specific product revenues included EMPAVELI at $19.73 million, below the average estimate of $23.67 million, and SYFOVRE at $130.17 million, which also fell short of the $156.94 million average estimate [4] Stock Performance - Over the past month, shares of Apellis Pharmaceuticals have returned +2.3%, underperforming compared to the Zacks S&P 500 composite's +10.6% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]